Frederic EYVRARD

Dr. Frederic EYVRARD

Centre Hospitalier Universitaire de Toulouse, Toulouse, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2016 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LHLaurent Hauviller
Laurent Hauviller
FEFrederic EYVRARD
Frederic EYVRARD
VGValérie Garnault
Valérie Garnault
VRVanessa Rousseau
Vanessa Rousseau
LML. Molinier
L. Molinier
HBHaleh Bagheri
Haleh Bagheri

4 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JZJeremie Zerbit
Jeremie Zerbit
MDMarion Detroit
Marion Detroit
SCSylvie Chevret
Sylvie Chevret
FPFrédéric Pène
Frédéric Pène
CLCharles-Edouard Luyt
Charles-Edouard Luyt
MKMarie Kroemer
Marie Kroemer
Background. Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19. Methods. We conducted a retrospective real-life study that included all patients from the early access program of remdesivir in France. The primary endpoint was the clinical course evolution of critically ill and hospitalized COVID-19 patients treated with remdesivir. Secondary endpoints were the SOFA score evolution within 29 days following the admission and mortality at 29 and 90 days. Results. Eighty-five patients were enrolled in 22 sites from January to April 2020. The median WHO and SOFA scores were respectively reduced by two and six points between days 1 and 29. Improvement in the WHO-CPS and the SOFA score were observed in 83.5% and 79.3% of patients, respectively, from day 10. However, there was no effect of remdesivir on the 90-day survival based on the control cohort for hospitalized COVID-19 patients with invasive ventilation. Conclusions. SOFA score appeared to be an attractive approach to assess remdesivir efficacy and stratify its utilization or not in critically ill patients with COVID-19. This study brings a new clinical benchmark for therapeutic decision making and supports the use of remdesivir for some hospitalized COVID-19 patients.

1 January 2018 in Actualites Pharmaceutiques
Verified
Journal Article
Closed access
SQSoraya Qassemi
Soraya Qassemi
CMChristelle Mouchoux
Christelle Mouchoux
FEFrederic EYVRARD
Frederic EYVRARD
NTNathalie Tesquet
Nathalie Tesquet
LRLaure Rouch
Laure Rouch
PCPhilippe Cestac
Philippe Cestac

1 February 2024 in The Lancet HIV
Verified
Journal Article
Closed access
LTLaure Tribaudeau
Laure Tribaudeau
FEFrederic EYVRARD
Frederic EYVRARD

1 March 2014 in Therapies
Verified
Journal Article
Closed access
PDF file
LPLiselotte Pochard
Liselotte Pochard
LHLaurent Hauviller
Laurent Hauviller
LCLise Cuzin
Lise Cuzin
FEFrederic EYVRARD
Frederic EYVRARD
ASAgnès Sommet
Agnès Sommet
HBHaleh Bagheri
Haleh Bagheri

26 February 2021 in L'Encéphale
Verified
Journal Article
Closed access
FEFrederic EYVRARD
Frederic EYVRARD
SMS. Metivier
S. Metivier
SSS.C. Sorli
S.C. Sorli
LCL. Cabrit
L. Cabrit
AJA. Jullien
A. Jullien
PCP. Cestac
P. Cestac